Published in J Neurochem on December 01, 1986
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov (2009) 3.26
Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol Aging (2008) 0.98
Bipolar disorder and neurophysiologic mechanisms. Neuropsychiatr Dis Treat (2008) 0.87
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. Br J Pharmacol (2005) 0.84
Age-dependent decrease in the affinity of muscarinic M1 receptors in neocortex of rhesus monkeys. Proc Natl Acad Sci U S A (1991) 0.83
Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. J Psychiatry Neurosci (1993) 0.83
Brain imaging of nicotinic receptors in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.82
Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. J Neural Transm (Vienna) (2008) 0.78
Α4β2 and α7 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks. Neuroscience (2012) 0.78
Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice. Front Aging Neurosci (2014) 0.78
Endogenously expressed muscarinic receptors in HEK293 cells augment up-regulation of stably expressed α4β2 nicotinic receptors. J Biol Chem (2011) 0.77
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology (Berl) (2008) 0.77
Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging (2016) 0.76
Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices. Br J Pharmacol (2002) 0.75
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acquir Immune Defic Syndr (1993) 2.36
Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci (1996) 1.78
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand (2009) 1.75
Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol (1999) 1.55
Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol (1994) 1.53
Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol (1991) 1.49
Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci (1997) 1.43
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol (2010) 1.30
Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol (1997) 1.27
Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol (1997) 1.27
Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science (1985) 1.26
Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.24
High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther (1994) 1.21
Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res (1997) 1.19
MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology (2011) 1.19
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol (1999) 1.19
Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr (1994) 1.18
Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol (2005) 1.14
Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience (1986) 1.13
Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem (1991) 1.03
Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem (1995) 1.01
Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol (1999) 0.99
Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol (1992) 0.99
Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci Lett (1986) 0.98
The M5 (m5) receptor subtype: fact or fiction? Life Sci (1997) 0.98
Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann Neurol (1988) 0.97
DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet (2004) 0.97
Brain-stimulation reward thresholds raised by an antisense oligonucleotide for the M5 muscarinic receptor infused near dopamine cells. J Neurosci (2000) 0.96
Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol (1999) 0.95
Response of F344 rats to inhalation of subclinical levels of sarin: exploring potential causes of Gulf War illness. Toxicol Ind Health (2001) 0.94
Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci (1997) 0.94
Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl Psychiatry (2013) 0.94
Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res (1997) 0.94
Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging (1997) 0.92
Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims. Mol Psychiatry (2006) 0.91
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res (2001) 0.90
Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol (1996) 0.89
Characterization and distribution of transferrin receptors in the rat brain. J Neurochem (1990) 0.88
Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav (1991) 0.88
Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging (1989) 0.88
Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain. Brain Res Mol Brain Res (2000) 0.87
Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol (1993) 0.86
Somatic sensory projections to the pretectum in the cat. Brain Res (1978) 0.86
Different effects of N-ethylmaleimide on M1 and M2 muscarine receptors in rat brain. Proc Natl Acad Sci U S A (1985) 0.86
Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem (1994) 0.86
Characterization of kappa1-opioid receptor binding in human insular cortex. Life Sci (1999) 0.85
Effect of relative humidity on aerosol persistence of Streptococcus salivarius. Arch Environ Health (1971) 0.85
In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther (2001) 0.85
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm (Vienna) (2003) 0.84
Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos (1998) 0.84
Drug interactions with the dopamine transporter in cryopreserved human caudate. J Pharmacol Exp Ther (2001) 0.84
The interaction of Ca2+/Mg2+ ATPase activator protein and Ca2+ with human erythrocyte membranes. Biochem Biophys Res Commun (1978) 0.84
Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand (2005) 0.83
Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors. Mol Pharmacol (1992) 0.83
Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse (1995) 0.83
Spatial memory in aged rats is related to PKCgamma-dependent G-protein coupling of the M1 receptor. Neurobiol Aging (2005) 0.83
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. J Neural Transm (Vienna) (2006) 0.83
Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis. Neuropharmacology (2000) 0.82
Localization of muscarinic receptor subtypes in brain stem areas regulating sleep. Neuroreport (1994) 0.81
Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry (2005) 0.81
Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci (1995) 0.81
Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev (2001) 0.81
Dopamine transporter mRNA in autopsy studies of chronic cocaine users. Brain Res Mol Brain Res (1999) 0.81
Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse (1993) 0.81
Circadian variations in radioligand binding to muscarine receptors in rat brain dependent upon endogenous agonist occupation. Brain Res (1985) 0.80
Semi-quantitative reverse-transcriptase polymerase chain reaction: an approach for the measurement of target gene expression in human brain. Brain Res Brain Res Protoc (1999) 0.80
Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett (2000) 0.80
Enzymatic methylation of the membrane-bound nicotinic acetylcholine receptor. J Biol Chem (1982) 0.80
Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Brain Res Mol Brain Res (1992) 0.80
The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport (1995) 0.79
Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids Chem Biol (2001) 0.79
Diminished muscarinic receptor-stimulated [3H]-PIP2 hydrolysis in Alzheimer's disease. Life Sci (1993) 0.79
Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol (1995) 0.79
Expression of glutamatergic genes in healthy humans across 16 brain regions; altered expression in the hippocampus after chronic exposure to alcohol or cocaine. Genes Brain Behav (2014) 0.78
21-aminosteroids interact with the dopamine transporter to protect against 1-methyl-4-phenylpyridinium-induced neurotoxicity. J Neurochem (1992) 0.78
Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. Neuroreport (1998) 0.78
Pargyline-sensitive selective accumulation of a radiolabeled MPTP analog in the primate cerebral cortex and basal ganglia. Synapse (1990) 0.78
Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Ann N Y Acad Sci (2000) 0.77
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology (Berl) (1996) 0.77
Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J Pharmacol Exp Ther (1989) 0.77
Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. Mol Pharmacol (1994) 0.77
Pharmacological characterization of the vesamicol analogue (+)-[(125)I]MIBT in primate brain. Eur J Pharmacol (1997) 0.77
Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential. Ann N Y Acad Sci (1998) 0.76
Characterization and localization of galanin receptors in human entorhinal cortex. Regul Pept (1998) 0.76
Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson's disease? Acta Neurol Scand (2006) 0.75
Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? Mol Psychiatry (1997) 0.75
Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. J Anal Toxicol (1995) 0.75
[3H]-(+)-pentazocine binding to sigma recognition sites in human cerebellum. Life Sci (1994) 0.75
Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine. Nat Prod Res (2006) 0.75
The effect of ischemic cerebrovascular disease on the clinical characteristics of Parkinson's disease. A post-mortem study. Eur J Neurol (2006) 0.75